These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28223037)

  • 1. Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism.
    Monnot C; Zhang X; Nikkhou-Aski S; Damberg P; Svenningsson P
    Exp Neurol; 2017 Jun; 292():11-20. PubMed ID: 28223037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
    Winkler C; Kirik D; Björklund A; Cenci MA
    Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy.
    Westin JE; Janssen ML; Sager TN; Temel Y
    Behav Brain Res; 2012 Jan; 226(2):519-28. PubMed ID: 22008381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    Eur J Pharmacol; 2000 Nov; 407(3):281-91. PubMed ID: 11068024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
    Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
    PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
    Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
    Alvarsson A; Zhang X; Stan TL; Schintu N; Kadkhodaei B; Millan MJ; Perlmann T; Svenningsson P
    J Neurosci; 2015 Oct; 35(41):14057-69. PubMed ID: 26468205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
    Fang C; Yin J; Xu Z; Wang Y; Xu H; Zhou H; Gao C
    Cell Biochem Biophys; 2011 Jan; 59(1):49-56. PubMed ID: 20714825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
    Kamińska K; Lenda T; Konieczny J; Wardas J; Lorenc-Koci E
    Neurochem Int; 2018 Dec; 121():125-139. PubMed ID: 30290201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of the acoustic startle response by dopamine agonists after 6-hydroxydopamine lesions of the substantia nigra pars compacta: corresponding changes in c-Fos expression in the caudate-putamen.
    Meloni EG; Davis M
    Brain Res; 2000 Oct; 879(1-2):93-104. PubMed ID: 11011010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-DOPA modulation of corpus striatal dopamine and dihydroxyphenylacetic acid output from intact and 6-OHDA lesioned rats.
    Xu K; Dluzen DE
    J Neural Transm (Vienna); 1996; 103(11):1295-305. PubMed ID: 9013416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling nigrostriatal degeneration in organotypic cultures, a new ex vivo model of Parkinson's disease.
    Daviaud N; Garbayo E; Lautram N; Franconi F; Lemaire L; Perez-Pinzon M; Montero-Menei CN
    Neuroscience; 2014 Jan; 256():10-22. PubMed ID: 24161279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
    Barnum CJ; Eskow KL; Dupre K; Blandino P; Deak T; Bishop C
    Neuroscience; 2008 Sep; 156(1):30-41. PubMed ID: 18687386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic transplants suppress L-DOPA-induced Fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
    Ishida Y; Kuwahara I; Todaka K; Hashiguchi H; Nishimori T; Mitsuyama Y
    Brain Res; 1996 Jul; 727(1-2):205-11. PubMed ID: 8842399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.
    Taylor MD; De Ceballos ML; Rose S; Jenner P; Marsden CD
    Eur J Pharmacol; 1992 Aug; 219(2):183-92. PubMed ID: 1385171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a 6-OHDA Induced Unilaterally Lesioned Male Wistar Rat Model of Parkinson's Disease.
    Kumari N; Luthra PM
    Methods Mol Biol; 2024; 2761():491-498. PubMed ID: 38427257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment.
    Quik M; Police S; He L; Di Monte DA; Langston JW
    Neuroscience; 2000; 98(2):263-73. PubMed ID: 10854757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
    Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Bishop C
    Behav Brain Res; 2014 Aug; 270():75-85. PubMed ID: 24837745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.